Approved by Health Canada - Zilia Ocular: A World First Set to Revolutionize Eye Care

QUEBEC CITY, June 19, 2025 /CNW/ - Zilia, a Canadian health technology company, is proud to announce that its flagship product, the Zilia Ocular™, has received approval from Health Canada. It is the first device in the world authorized to measure oxygen saturation in the eye—a breakthrough that has the potential to redefine eye care.
Developed in Quebec City, the Zilia Ocular is a revolutionary retinal camera equipped with a patented optical technology that enables the non-invasive measurement of oxygenation in the eye. This metabolic biomarker gives eye care professionals an entirely new window into the physiological state of the eye, with the goal of detecting issues well before structural damage occurs.
"This represents a true paradigm shift," said Dr. Patrick Sauvageau, optometrist, CEO and co-founder of Zilia. "By measuring retinal oxygenation in real time, we aim to help clinicians detect and manage eye diseases such as glaucoma, diabetic retinopathy, and age-related macular degeneration more effectively."
A Breakthrough at the Heart of Oculomics
As oculomics—an emerging field that uses the eye as a gateway to assess overall health—gains traction globally, biomarkers like oxygen saturation are paving the way for a more preventive, personalized, and data-driven approach to medicine. The Zilia Ocular is at the forefront of this movement, introducing a layer of analysis that was previously inaccessible in clinical settings.
Zilia plans to launch its device in Canada in the coming months, followed by expansion into the United States and Europe.
About Zilia
Zilia is a health technology company developing a groundbreaking platform to non-invasively measure biomarkers in the eye, with an initial focus on ocular oximetry. By integrating advanced photonics and artificial intelligence, Zilia's first-of-kind technology is intended to leverage the eye's optical properties and direct connections to the vascular system and the brain to capture critical information on ocular and overall health.

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Global News

an hour ago

• Global News

EV interest is stalling over cost concerns. Could a consumer rebate help?

Demand for electric vehicles around the world appears to be on the decline, according to a recent survey from Shell that says cost and affordability are key concerns for buyers. At the same time, the Canadian government confirmed this week that it is exploring a new consumer rebate for electric vehicles. Statistics Canada reported that in the first quarter, or three months, of this year, 37,299 new zero-emission vehicles (ZEVs) were registered, making up 8.7 per cent of all new motor vehicle registrations, down more than 23 per cent compared with one year prior. For the month of April, the latest update from Statistics Canada, EV sales accounted for just over 7.5 per cent of all vehicles sold in Canada. Why are consumers less interested in electric vehicles? New data shows that overall, consumers who haven't bought an EV already say it's primarily due to the costs of purchasing and owning one for the long term. Story continues below advertisement Shell Global released the results of a survey on Tuesday showing falling demand for electric vehicles, especially in Europe and the United States, with affordability the main reason cited, along with charging network reliability. Meanwhile, the report shows that more than two-thirds of current electric vehicle owners reported feeling less worried about charging concerns than a year prior, and nearly three-quarters say the options and availability of public charging points have improved. Although the Shell Global survey did not poll Canadians, there are consistent findings in other recent reports that did. An AutoTrader survey conducted in 2024 found that non-owners in Canada are hesitant to purchase an electric vehicle due to 'limited travel range/distance, inadequate availability of charging stations, higher purchasing costs, and the belief that EVs are unsuitable for cold weather.' 'Overall, while almost half of non-EV owners are open to buying an EV for their next vehicle, interest in EVs has declined for the second year in a row,' Tiffany Ding, director of Insights and Intelligence at AutoTrader, said last year. Get daily National news Get the day's top news, political, economic, and current affairs headlines, delivered to your inbox once a day. Sign up for daily National newsletter Sign Up By providing your email address, you have read and agree to Global News' Terms and Conditions and Privacy Policy AutoTrader also confirmed at the time that there was a direct correlation between lower gas prices and lower demand for electric vehicles, and vice versa. 2:01 With Trump administration incoming, what will happen to Canada's EV plan? In early 2022, demand for electric vehicles peaked worldwide as the price of traditional gasoline spiked and consumers sought alternatives. Story continues below advertisement This was in addition to strained supply chains, which made traditional gas-powered vehicles more expensive along with other products, and a lack of preparedness for the change in consumer demands made it harder for car companies to keep up. By the end of 2022, things changed direction as supply chains caught up with demand, and affordability started to take a toll on households amid high inflation and rising interest rates. The AutoTrader survey found that drivers instead were looking more and more to hybrid options, including plug-in hybrids, which offer the benefits of both a gas engine and electric by not relying as much or at all on a charging network and consuming less traditional gasoline overall. 6:01 Where does Canada's EV industry currently stand? Prices have also been gradually declining for some electric vehicles, so it is possible car companies are taking note of a drop in demand and cost concerns. Story continues below advertisement In some cases, this has also meant delaying plans for expanding EV production. According to the average price for a new EV in Canada as of December 2024 was $70,682, which is down 7.8 per cent from a year earlier, while used options averaged $42,045, a drop of 18.4 per cent from 2024. Canadians can currently purchase some of the cheaper electric vehicle options brand new, starting at roughly $40,000. There is also the cost of charging, which may include the purchase and installation of a home charger, vehicle maintenance specific to electric vehicles, as well as depreciation over time, which differs compared with some gas-powered versions. AutoTrader's price index for the first quarter of 2025 pinned the national average price for a new vehicle at $65,564 — down almost three per cent year over year — and the national average price for a used vehicle at $36,823, a drop of 2.2 per cent year over year. Could a rebate help? Responding to reporters on Tuesday outside the House of Commons, Environment Minister Julie Dabrusin said 'there will be a consumer rebate,' with few other details given for now. Story continues below advertisement 'Will it be named, iZEV? That I can't tell you,' Dabrusin said when asked by reporters earlier this week about a future rebate program for EVs. This followed a meeting in which the Opposition Conservatives called for current electric vehicle mandates to be scrapped, including the Trudeau government's goal to have all new consumer passenger vehicles and light trucks sold in Canada be zero-emission by 2035, citing concerns about the Canadian auto sector and U.S. President Donald Trump's tariff policies. As of now, Canada and the United States have imposed on each other a 25 per cent tariff on all automotive imports that do not comply with the current North American trade deal known as the Canada-United States-Mexico Agreement (CUSMA). Canadian auto makers and other industry leaders also support ending these mandates, suggesting that the lack of consumer rebates or other incentives makes these goals unrealistic and a 'policy failure.' 2:32 BIV: Province pausing electric vehicle rebate program The iZev, or Incentives for Zero-Emission Vehicles, program was launched by the federal government in 2019 but ran out of funding by January of this year. Dabrusin's comments suggest it will be replaced with a new strategy aimed at making EVs more affordable for some Canadians. Story continues below advertisement The iZev was intended to act in addition to provincial electric vehicle rebates where available. Previously, the iZEV program offered up to $5,000 off the cost of a new electric vehicle, and over the nearly six-year life span, it cost the federal government nearly $3 billion.

Cision Canada

2 hours ago

• Cision Canada

Over $7.7M in Ontario-Based Platforms to Advance Open Science and Brain Health Innovation Français

Two cutting-edge platforms at CAMH and Western University aim to accelerate AI-driven brain research and global data sharing TORONTO, June 20, 2025 /CNW/ - Brain Canada is pleased to announce an investment of more than $7.7 million to support two innovative research platforms based in Ontario that will drive forward brain health discovery, data sharing, and open science collaboration. Funded through the Canada Brain Research Fund (CBRF), a visionary partnership between Brain Canada and the Government of Canada, through Health Canada, these two projects will provide Canadian and international researchers with the tools and infrastructure they need to transform how brain disorders are studied, understood, and treated. "Through the Canada Brain Research Fund, the Government of Canada is pleased to support these two essential and innovative research initiatives, which will help drive new discoveries and improve care for people affected by neurological conditions," said the Honourable Marjorie Michel, Minister of Health. The newly supported platforms are the Brain Health Data Challenge (BHDC) platform, led by Dr. Tristan Glatard at the Centre for Addiction and Mental Health (CAMH), and the Mesoscopic Integrated Neuroimaging Data (MIND) Platform, led by Dr. Ali Khan at Western University. "Canada is at the forefront of a global shift toward open science in brain research," said Dr. Viviane Poupon, President and CEO of Brain Canada. "These two platforms exemplify how we can responsibly share data, scale innovation, and build collaborative networks to unlock the full potential of neuroscience and AI." ABOUT THE PROJECTS Building Reproducible AI Frameworks for Brain Health with the Brain Health Data Challenge Platform Tristan Glatard, Centre for Addiction and Mental Health (CAMH) (Grant total: $4.9M) With vast amounts of brain health data now available, artificial intelligence is revolutionizing how we understand, diagnose, and treat neurological conditions. However, data privacy regulations often prevent this information from being used in open AI challenges—a key method that has already accelerated innovation in fields like cancer and medical imaging. The BHDC platform will create a secure, privacy-compliant framework to enable AI competitions using Canadian brain health data. By unlocking these datasets for responsible and collaborative use, the platform will foster the development of reproducible and equitable AI models, helping clinicians tailor treatments and improve care for people living with brain disorders. "With this transformative investment from Brain Canada, CAMH is proud to lead the development of a secure and robust framework for ethical AI in mental health," said Dr. Aristotle Voineskos, SVP of Research and Science, CAMH. "The Brain Health Data Challenge will empower researchers globally to address complex brain health questions using advanced data science—while upholding the highest standards of privacy and equity. By enabling predictive, reproducible AI for serious mental illness, we move closer to better care, earlier interventions and improved quality of life." The Mesoscopic Integrated Neuroimaging Data (MIND) Platform Ali Khan, Western University (Grant total: $2.9 million) The MIND Platform combines ultra-powerful MRI and lightsheet microscopy, which enables researchers to see the brain's structure and activity in unprecedented detail. By linking images of living brains with detailed microscopy of brain tissue, scientists can gain deeper insights into how diseases like Alzheimer's or Parkinson's progress, affect brain circuits, and can be treated. The MIND Platform builds on two internationally recognized imaging facilities at Western University to create a centralized, standardized repository for high-resolution brain tissue data. Through a user-friendly online portal, researchers around the world will be able to send brain tissue for imaging and access powerful tools to analyze the data—without requiring advanced infrastructure at every site. By adopting global data standards and a robust open science framework, the MIND Platform will fuel national and international collaboration, enabling deeper understanding of brain structure, function, and disease. "Western is internationally recognized for its strengths in neuroimaging, with a long history of innovation and collaboration," said Robert Bartha, Vice Dean of Research and Innovation at Western's Schulich School of Medicine & Dentistry. "The MIND Platform builds on that foundation, pairing powerful imaging technologies with open science to push the boundaries of how we explore and understand the brain." Together, these platforms mark a major step forward in Canada's leadership in brain research, making it easier for scientists to share knowledge, build on each other's work, and transform brain health through open, data-driven innovation. About Brain Canada Brain Canada is a national charitable organization that enables and supports excellent, innovative, and collaborative brain research in Canada. Through the Canada Brain Research Fund, a public-private partnership with the Government of Canada through Health Canada, Brain Canada funds initiatives that advance knowledge, drive innovation, and accelerate the development of diagnostics, treatments, and cures. About the Centre for Addiction and Mental Health (CAMH) The Centre for Addiction and Mental Health (CAMH) is Canada's largest mental health and addiction teaching hospital and a world leading research centre in this field. CAMH combines clinical care, research, education, policy development and health promotion to help transform the lives of people affected by mental illness and addiction. CAMH is fully affiliated with the University of Toronto and is a Pan American Health Organization/World Health Organization Collaborating Centre. For more information, please visit or follow @CAMHnews on Bluesky and LinkedIn. About Western University Western University delivers an academic experience second to none. Since 1878, The Western Experience has combined academic excellence with life-long opportunities for intellectual, social and cultural growth in order to better serve our communities. Our research excellence expands knowledge and drives discovery with real-world application. Western attracts individuals with a broad worldview, seeking to study, influence and lead in the international community. CAMH [email protected] Western University Crystal Mackay Director, Media Relations m. 519-933-5944 e. [email protected] Brain Canada Kate Shingler, Senior Director, Strategic Communications [email protected] 514-550-8308 SOURCE Brain Canada

Cision Canada

3 hours ago

• Cision Canada

With Public Funding Under Pressure, Biotech Innovators Are Picking Up the Slack in Oncology

VANCOUVER, BC, June 20, 2025 /CNW/ -- USA News Group News Commentary – The costs of cancer drugs is skyrocketing, according to a recent report from Bloomberg. Analysts at Nova One Advisor estimate that the global oncology drugs market will grow at a 7.4% CAGR through to US$366.24 billion by 2034. Help doesn't appear to be coming from the public sector, as reports state that the current US administration could drastically reduce funding of the National Cancer Institute (NCI) by nearly 40%, the market is looking towards the private sector to pick up the slack and continue to make advancements in cancer treatment. For investors to note, plenty of oncology innovators have provided recent developments, including Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), Immuneering Corporation (NASDAQ: IMRX), GRAIL, Inc. (NASDAQ: GRAL), Intensity Therapeutics, Inc. (NASDAQ: INTS), and Relay Therapeutics, Inc. (NASDAQ: RLAY). The global oncology market is expected to see strong growth over the next decade, with ResearchAndMarkets forecasting it to reach US$866.1 billion by 2034 at a 10.8% CAGR. A separate estimate from Vision Research Reports projects the market will surpass US$903.81 billion by the same year, growing at a 10.9% CAGR. Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC) has entered a new phase of leadership with the appointment of Jared Kelly as Chief Executive Officer and member of the Board. Kelly brings a background in high-stakes biotech transactions and strategic immuno-oncology development, positioning him to guide the company through its next stage of clinical and business evolution. Before joining Oncolytics, Kelly served as General Counsel at Ambrx Biopharma, where he played a key role in its $2 billion acquisition by Johnson & Johnson. His earlier work includes advising life sciences firms on licensing, partnerships, and M&A while at Kirkland & Ellis LLP and Lowenstein Sandler LLP. Now leading Oncolytics, he steps into a company advancing pelareorep, a virus-based immunotherapeutic designed to work synergistically with checkpoint inhibitors and other agents across a range of solid and blood cancers. "Pelareorep's clinical data across multiple tumors is striking and represents the potential for a true backbone immunotherapy to address many in-need indications. Importantly, the data show that pelareorep creates a robust immunologic response in difficult tumors and increases survival in a patient population where survival has historically evaded most patients," said Jared Kelly, CEO of Oncolytics Biotech. "With a renewed focus and sharpened clinical development plan, we believe we will move pelareorep forward effectively and efficiently to a place where potential partners will see the value of a de-risked immunotherapy. I am excited to get to work accelerating development and unlocking significant value for stakeholders." Kelly's appointment signals a clear strategic focus: advancing pelareorep toward key late-stage milestones through a capital-conscious approach that remains open to strategic collaboration. Pelareorep currently holds FDA Fast Track designation for both metastatic pancreatic ductal adenocarcinoma (mPDAC) and HR+/HER2- metastatic breast cancer (mBC) —a rare dual recognition that underscores its regulatory momentum. Across multiple studies, the virus-based therapy has demonstrated consistent immune activation, broad combinability with checkpoint inhibitors and chemotherapies, and encouraging response rates in challenging cancer types. In mPDAC, pelareorep has achieved over 60% objective response rates in tumor-evaluable patients across Phase 1 and 2 trials—more than double what's typically seen in historical benchmarks. Separate analyses also reported two-year survival rates four to six times higher than control arms or prior studies. In HR+/HER2- mBC, two randomized Phase 2 trials (IND-213 and BRACELET-1) showed survival benefits supportive of further investigation. Meanwhile, a Phase 2 cohort in anal cancer pairing pelareorep with a checkpoint inhibitor reported partial or complete responses in nearly half of evaluable patients—substantially higher than historical norms for monotherapy in this setting. "Mr. Kelly's vision and track record is an extraordinary fit with the standout clinical data pelareorep has generated to date," said Wayne Pisano, Chair of the Board and outgoing Interim CEO of Oncolytics. "We believe Mr. Kelly's well-documented ability to prioritize clinical program development, execute successful financings, and attract the attention of large industry peers will help maximize Oncolytics' potential to deliver transformative outcomes for patients and exceptional value for investors." Kelly's compensation package includes equity grants and milestone-linked incentives tied to future financings and potential strategic transactions—aligning leadership priorities with long-term shareholder interests. The structure signals a commitment to advancing both clinical and corporate goals while preserving balance sheet discipline and maintaining appeal for potential partners. With multiple cohorts progressing in the GOBLET study—including those in pancreatic and anal cancer supported by external funding and regulatory engagement— Oncolytics is positioned to move forward with a combination of scientific momentum, financial agility, and renewed strategic focus. In other recent industry developments and happenings in the market include: Immuneering Corporation (NASDAQ: IMRX) reported positive Phase 2a data for atebimetinib (IMM-1-104) in combination with modified gemcitabine/nab-paclitaxel in first-line pancreatic cancer patients. At six months, the study showed 94% overall survival and 72% progression-free survival in 34 patients, with no median OS or PFS reached yet. "These exceptional data demonstrate the potential of atebimetinib plus mGnP to dramatically extend the lives of patients with advanced pancreatic cancer," said Ben Zeskind, Ph.D., Co-founder and CEO of Immuneering. "Our ultimate goal is to help cancer patients outlive their disease, and today's announcement represents an important milestone on that journey." The combination also demonstrated a 39% overall response rate, an 81% disease control rate, and a notably favorable tolerability profile. Many patients experienced deep, durable tumor regressions, including lesions rendered undetectable. The regimen was well tolerated, with an adverse event profile suggesting potential best-in-class positioning among MEK inhibitors. GRAIL, Inc. (NASDAQ: GRAL), recently announced strong top-line results from the PATHFINDER 2 registrational study evaluating its Galleri® multi-cancer early detection test in over 25,000 adults. "We are delighted to see very encouraging performance of the Galleri MCED test as a cancer screening tool in broad intended use populations of asymptomatic adults over 50 years of age in both the PATHFINDER 2 study and the NHS-Galleri trial's prevalent screening round," said Josh Ofman, MD, MSHS, President at GRAIL. "We would like to extend our sincere gratitude to all of the participants and investigators in both of these pivotal studies, who are collectively helping to realize the potential of this groundbreaking technology for population-scale multi-cancer early detection and move the field forward." The study showed a substantially higher positive predictive value (PPV) compared to the original PATHFINDER trial, with consistent specificity and cancer signal origin accuracy, and no serious safety concerns reported. GRAIL plans to submit these results to the FDA as part of its ongoing premarket approval process under Breakthrough Device Designation. Intensity Therapeutics, Inc. (NASDAQ: INTS) announced that the first patients in its ongoing Phase 2 INVINCIBLE-4 trial achieved high levels of tumor necrosis within eight days of receiving two doses of INT230-6, before starting standard-of-care immunochemotherapy for triple-negative breast cancer (TNBC). "We are excited to see that INT230-6 is achieving meaningful levels of necrosis in patients with evidence of immune activation," said Lewis H. Bender, President and CEO of Intensity. "TNBC patients risk their lives to achieve a pCR, and about forty percent fail to achieve the desired result." MRI scans showed substantial tumor destruction and inflammation, suggesting immune activation following direct intratumoral injection. The randomized study compares INT230-6 followed by standard treatment versus standard treatment alone, with pathological complete response (pCR) as the primary endpoint. Relay Therapeutics, Inc. (NASDAQ: RLAY) reported updated interim data from its Phase 1/2 study of RLY-2608 plus fulvestrant, showing a median progression-free survival (PFS) of 11.0 months in second-line patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer. "We are encouraged by the consistency of these updated RLY-2608 + fulvestrant data, which continue to show the potential benefit of a mutant-selective PI3Kα inhibitor for improving both the tolerability profile and progression free survival compared to standard of care," said Don Bergstrom, M.D., Ph.D., President of R&D at Relay Therapeutics. "We look forward to starting the first mutant-selective PI3Kα Phase 3 trial, ReDiscover-2, in the middle of this year." Among patients at the recommended Phase 3 dose, the clinical benefit rate reached 67%, and 39% had confirmed partial responses, with notably higher response rates in those with kinase mutations. The combination maintained a favorable tolerability profile, with low rates of high-grade adverse events and minimal treatment discontinuations. DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. USA News Group is a wholly-owned subsidiary of Market IQ Media Group, Inc. ("MIQ"). MIQ has been paid a fee for Oncolytics Biotech Inc. advertising and digital media from the company directly. There may be 3rd parties who may have shares of Oncolytics Biotech Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Oncolytics Biotech Inc. which were purchased in the open market, and reserve the right to buy and sell, and will buy and sell shares of Oncolytics Biotech Inc. at any time without any further notice commencing immediately and ongoing. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material, including this article, which is disseminated by MIQ has been approved by Oncolytics Biotech Inc.; this is a paid advertisement, we currently own shares of Oncolytics Biotech Inc. and will buy and sell shares of the company in the open market, or through private placements, and/or other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.